- Home
- AGIO vs RXO Comparison
AGIO vs RXO Comparison
Compare AGIO & RXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- RXO
- Stock Information
- Founded
- AGIO 2007
- RXO 2022
- Country
- AGIO United States
- RXO United States
- Employees
- AGIO N/A
- RXO N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- RXO
- Sector
- AGIO Health Care
- RXO
- Exchange
- AGIO Nasdaq
- RXO Nasdaq
- Market Cap
- AGIO 2.4B
- RXO 2.6B
- IPO Year
- AGIO 2013
- RXO N/A
- Fundamental
- Price
- AGIO $40.16
- RXO $13.66
- Analyst Decision
- AGIO Strong Buy
- RXO Hold
- Analyst Count
- AGIO 4
- RXO 15
- Target Price
- AGIO $59.33
- RXO $18.08
- AVG Volume (30 Days)
- AGIO 567.8K
- RXO 1.8M
- Earning Date
- AGIO 10-30-2025
- RXO 11-06-2025
- Dividend Yield
- AGIO N/A
- RXO N/A
- EPS Growth
- AGIO N/A
- RXO N/A
- EPS
- AGIO N/A
- RXO N/A
- Revenue
- AGIO $44,791,000.00
- RXO $5,940,000,000.00
- Revenue This Year
- AGIO $25.57
- RXO $30.18
- Revenue Next Year
- AGIO $153.24
- RXO $6.30
- P/E Ratio
- AGIO N/A
- RXO N/A
- Revenue Growth
- AGIO 36.26
- RXO 53.85
- 52 Week Low
- AGIO $23.42
- RXO $12.19
- 52 Week High
- AGIO $62.58
- RXO $31.98
- Technical
- Relative Strength Index (RSI)
- AGIO 45.66
- RXO 30.03
- Support Level
- AGIO $38.90
- RXO $17.00
- Resistance Level
- AGIO $44.10
- RXO $17.81
- Average True Range (ATR)
- AGIO 1.72
- RXO 0.86
- MACD
- AGIO -0.44
- RXO -0.30
- Stochastic Oscillator
- AGIO 24.58
- RXO 0.00
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.